文献速递甲状腺疾病

精准医学时代放射性碘难治性甲状腺癌中的G蛋白偶联受体

G Protein-coupled Receptors in Radioiodine-refractory Thyroid Cancer in the Era of Precision Medicine.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

本研究对17例放射性碘难治性甲状腺癌患者的肿瘤与正常甲状腺组织进行371个G蛋白偶联受体(GPCR)mRNA表达谱分析,发现滤泡状癌中4个受体下调,乳头状癌中24个受体失调,其中22个GPCR为已上市药物的靶点,为药物重定位和精准医学提供潜在靶点。

要点

  • 在放射性碘难治性甲状腺癌中首次系统描绘GPCR表达图谱。
  • 滤泡状癌中VIPR1、ADGRL2/LPHN2、ADGRA3和ADGRV1表达下调。
  • 乳头状癌中24个受体失调,22个GPCR为已批准药物的靶点。

核心结论

  • 在进展性和难治性甲状腺癌中首次完成GPCR mRNA表达谱分析,为药物重定位和精准医学提供潜在治疗靶点。

研究设计与样本

  • 分析17例难治性甲状腺癌患者(12例乳头状癌和5例滤泡状癌)的肿瘤与正常甲状腺组织,采用NanoString技术检测371个GPCR的mRNA表达。

主要发现

  • 滤泡状癌中4个受体下调:VIPR1、ADGRL2/LPHN2、ADGRA3和ADGRV1。
  • 乳头状癌中24个受体失调,其中7个经公共数据集生物信息学分析验证:VIPR1、ADORA1、GPRC5B、P2RY8、GABBR2、CYSLTR2和LPAR5。
  • 差异表达基因中22个GPCR为已批准药物的靶点,部分GPCR与预后因素相关。

临床怎么用

  • 研究提示部分GPCR可作为放射性碘难治性甲状腺癌药物重定位的潜在靶点,但尚未转化为临床推荐。

局限性

  • 样本量较小(17例),需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Radioiodine-refractory thyroid cancers have poor outcomes and limited therapeutic options (tyrosine kinase inhibitors) due to transient efficacy and toxicity of treatments. Therefore, combinatorial treatments with new therapeutic approaches are needed. Many studies link G protein-coupled receptors (GPCRs) to cancer cell biology. OBJECTIVE: To perform a specific atlas of GPCR expression in progressive and refractory thyroid cancer to identify potential targets among GPCRs aiming at drug repositioning. METHODS: We analyzed samples from tumor and normal thyroid tissues from 17 patients with refractory thyroid cancer (12 papillary thyroid cancers [PTCs] and 5 follicular thyroid cancers [FTCs]). We assessed GPCR mRNA expression using NanoString technology with a custom panel of 371 GPCRs. The data were compared with public repositories and pharmacological databases to identify eligible drugs. The analysis of prognostic value of genes was also performed with TCGA datasets. RESULTS: With our transcriptomic analysis, 4 receptors were found to be downregulated in FTC (VIPR1, ADGRL2/LPHN2, ADGRA3, and ADGRV1). In PTC, 24 receptors were deregulated, 7 of which were also identified by bioinformatics analyses of publicly available datasets on primary thyroid cancers (VIPR1, ADORA1, GPRC5B, P2RY8, GABBR2, CYSLTR2, and LPAR5). Among all the differentially expressed genes, 22 GPCRs are the target of approved drugs and some GPCRs are also associated with prognostic factors. DISCUSSION: For the first time, we performed GPCR mRNA expression profiling in progressive and refractory thyroid cancers. These findings provide an opportunity to identify potential therapeutic targets for drug repositioning and precision medicine in radioiodine-refractory thyroid cancer.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Suteau V, Seegers V, Munier M, et al. G Protein-coupled Receptors in Radioiodine-refractory Thyroid Cancer in the Era of Precision Medicine. J Clin Endocrinol Metab. 2021. PMID: 34000025. doi:10.1210/clinem/dgab343

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。